Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Genevieve J Kaunitz

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|November 13, 2016
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumorsLudmila Danilova, Hao Wang, Joel Sunshine, et al.
Journal for Immunotherapy of Cancer|July 7, 2021
Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevanceTricia Cottrell, Jiajia Zhang, Boyang Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2017
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody ComparisonJoel C Sunshine, Peter L Nguyen, Genevieve J Kaunitz, et al.
JAMA Oncology|March 24, 2017
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for ImmunotherapyElizabeth L Yanik, Genevieve J Kaunitz, Tricia R Cottrell, et al.
Journal of Cutaneous Pathology|June 27, 2018
Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesionsWei-Shen Chen, Michael T Tetzlaff, Hafeez Diwan, et al.
The American Journal of Surgical Pathology|August 18, 2017
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic PatternGenevieve J Kaunitz, Manisha Loss, Hira Rizvi, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 25, 2017
Melanoma subtypes demonstrate distinct PD-L1 expression profilesGenevieve J Kaunitz, Tricia R Cottrell, Mohammed Lilo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2017
Transcriptional Mechanisms of Resistance to Anti-PD-1 TherapyMaria L Ascierto, Alvin Makohon-Moore, Evan J Lipson, et al.
Journal for Immunotherapy of Cancer|October 5, 2018
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumabNicolas A Giraldo, Peter Nguyen, Elizabeth L Engle, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Proceedings of the National Academy of Sciences of the United States of America|November 13, 2016
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumorsLudmila Danilova, Hao Wang, Joel Sunshine, et al.
Journal for Immunotherapy of Cancer|July 7, 2021
Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevanceTricia Cottrell, Jiajia Zhang, Boyang Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2017
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody ComparisonJoel C Sunshine, Peter L Nguyen, Genevieve J Kaunitz, et al.
JAMA Oncology|March 24, 2017
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for ImmunotherapyElizabeth L Yanik, Genevieve J Kaunitz, Tricia R Cottrell, et al.
Journal of Cutaneous Pathology|June 27, 2018
Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesionsWei-Shen Chen, Michael T Tetzlaff, Hafeez Diwan, et al.
The American Journal of Surgical Pathology|August 18, 2017
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic PatternGenevieve J Kaunitz, Manisha Loss, Hira Rizvi, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 25, 2017
Melanoma subtypes demonstrate distinct PD-L1 expression profilesGenevieve J Kaunitz, Tricia R Cottrell, Mohammed Lilo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2017
Transcriptional Mechanisms of Resistance to Anti-PD-1 TherapyMaria L Ascierto, Alvin Makohon-Moore, Evan J Lipson, et al.
Journal for Immunotherapy of Cancer|October 5, 2018
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumabNicolas A Giraldo, Peter Nguyen, Elizabeth L Engle, et al.
Pageof 1